Form 4: Twist Bioscience CEO Sells Shares
Insider Transaction (Form 4)
Emily M. Leproust, Chief Executive Officer and a Director of Twist Bioscience Corp, sold 4,548 shares of common stock on October 5, 2026.
Summary
- Open-market sale: disposed of 1,840 Common Stock at $200.44 ($368,806) on October 5, 2026; holds 565,468 after (Direct).
- Open-market sale: disposed of 481 Common Stock at $201.26 ($96,804) on October 5, 2026; holds 564,987 after (Direct).
- Open-market sale: disposed of 1,017 Common Stock at $202.32 ($205,763) on October 5, 2026; holds 563,970 after (Direct).
- Open-market sale: disposed of 432 Common Stock at $203.61 ($87,958) on October 5, 2026; holds 563,538 after (Direct).
- Open-market sale: disposed of 290 Common Stock at $204.80 ($59,392) on October 5, 2026; holds 563,248 after (Direct).
- Open-market sale: disposed of 297 Common Stock at $205.78 ($61,116) on October 5, 2026; holds 562,951 after (Direct).
- Open-market sale: disposed of 146 Common Stock at $206.84 ($30,199) on October 5, 2026; holds 562,805 after (Direct).
- Open-market sale: disposed of 45 Common Stock at $207.46 ($9,336) on October 5, 2026; holds 562,760 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $919,374 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Emily M. Leproust — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-05 | Open-market sale | Common Stock | 1,840 | $200 | $368.8K | 565,468 |
| 2026-10-05 | Open-market sale | Common Stock | 481 | $201 | $96.8K | 564,987 |
| 2026-10-05 | Open-market sale | Common Stock | 1,017 | $202 | $205.8K | 563,970 |
| 2026-10-05 | Open-market sale | Common Stock | 432 | $204 | $88.0K | 563,538 |
| 2026-10-05 | Open-market sale | Common Stock | 290 | $205 | $59.4K | 563,248 |
| 2026-10-05 | Open-market sale | Common Stock | 297 | $206 | $61.1K | 562,951 |
| 2026-10-05 | Open-market sale | Common Stock | 146 | $207 | $30.2K | 562,805 |
| 2026-10-05 | Open-market sale | Common Stock | 45 | $207 | $9.3K | 562,760 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-05 | Open-market sale (1,840 shares) |
| 2026-10-05 | Open-market sale (481 shares) |
| 2026-10-05 | Open-market sale (1,017 shares) |
| 2026-10-05 | Open-market sale (432 shares) |
| 2026-10-05 | Open-market sale (290 shares) |
| 2026-10-05 | Open-market sale (297 shares) |
| 2026-10-05 | Open-market sale (146 shares) |
| 2026-10-05 | Open-market sale (45 shares) |
Keywords
insider transaction, Form 4, TWST, Twist Bioscience Corp, bearish, Emily M. Leproust
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.